Patrick Forde, M.B.B.Ch.

Headshot of Patrick Forde
  • Co-Director, Division of Upper Aerodigestive Malignancies
  • Professor of Oncology

Languages: English, Irish


Clinical Trials, Lung Cancer, Medical Oncology, Mesothelioma, Non-Small Cell Lung Cancer, Pulmonary Carcinoid Tumors, Small Cell Lung Cancer more

Research Interests

Lung Cancer; Mesothelioma; Clinical Investigation


Skip Viragh Outpatient Cancer Center

201 N. Broadway
Baltimore, MD 21287
Phone: 410-955-8893 | Fax: 410-614-9334
Skip Viragh Outpatient Cancer Center - Google Maps

Johns Hopkins Bayview Medical Center

300 Mason Lord Drive
Sidney Kimmel Comprehensive Cancer Center
Baltimore, MD 21224
Phone: 410-550-1711 | Fax: 410-550-1116
Johns Hopkins Bayview Medical Center - Google Maps


Dr. Forde treats patients with lung cancer, mesothelioma, and other thoracic cancers. He completed training in internal medicine and oncology in Ireland prior to undertaking a further fellowship at Johns Hopkins. He is currently Co-Director of the Division of Upper Aerodigestive Malignancies in the Department of Oncology at Johns Hopkins and directs the multidisciplinary Thoracic Oncology Clinical Research Program.

He has led development of a clinical-translational research program focused on the immuno-oncology of upper aerodigestive malignancies. Dr. Forde's research examines the role of immunotherapy for mesothelioma and lung cancer and his work has led to the development of several ongoing phase 3 trials. In 2022, his work over several years, published in the New England Journal of Medicine, led to the FDA approval of neoadjuvant chemo-immunotherapy for the treatment of surgically operable lung cancer.

Dr. Forde serves as principal investigator for the thoracic cancer immunobiology biospecimen repository protocol at Johns Hopkins. He is focused on providing compassionate, state-of-the-art care for his patients in conjunction with a team of oncology specialist nurses, nurse practitioners, and dedicated staff. more


  • Co-Director, Division of Upper Aerodigestive Malignancies
  • Director, Thoracic Oncology Clinical Research Program
  • Professor of Oncology

Departments / Divisions

Centers & Institutes



  • MBBCh; Royal College of Surgeons in Ireland (2004)


  • Medical Oncology; Beaumont Hospital at RCSI (2009)
  • Medical Oncology; Mater Misericordiae University Hospital (2008)
  • Internal Medicine; Royal College of Physicians Ireland (2007)


  • Medical Oncology; Cork University Hospital (2010)
  • Oncology; Johns Hopkins University School of Medicine (2014)
  • Medical Oncology; St James's Hospital (2011)

Additional Training

Johns Hopkins Leadership Development Program 2020-21

Research & Publications

Selected Publications

View all on PubMed

Forde PM, Spicer J, Lu S, Provencio M, Mitsudomi T, Awad MM, Felip E, Broderick SR, Brahmer JR, Swanson SJ, Kerr K, Wang C, Ciuleanu TE, Saylors GB, Tanaka F, Ito H, Chen KN, Liberman M, Vokes EE, Taube JM, Dorange C, Cai J, Fiore J, Jarkowski A, Balli D, Sausen M, Pandya D, Calvet CY, Girard N. Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer. N Engl J Med. 2022 May 26;386(21):1973-1985

Forde PM, Anagnostou V, Sun Z, Dahlberg SE, Kindler HL, Niknafs N, Purcell T, Santana-Davila R, Dudek AZ, Borghaei H, Lanis M, Belcaid Z, Smith KN, Balan A, White JR, Cherry C, Ashok Sivakumar IK, Shao XM, Chan HY, Singh D, Thapa S, Illei PB, Pardoll DM, Karchin R, Velculescu VE, Brahmer JR, Ramalingam SS. Durvalumab with platinum-pemetrexed for unresectable pleural mesothelioma: survival, genomic and immunologic analyses from the phase 2 PrE0505 trial. Nat Med. 2021 Nov;27(11):1910-1920. doi: 10.1038/s41591-021-01541-0. Epub 2021 Nov 8. PMID: 34750557

Reuss JE, Anagnostou V, Cottrell TR, Smith KN, Verde F, Zahurak M, Lanis M, Murray JC, Chan HY, McCarthy C, Wang D, White JR, Yang S, Battafarano R, Broderick S, Bush E, Brock M, Ha J, Jones D, Merghoub T, Taube J, Velculescu VE, Rosner G, Illei P, Pardoll DM, Topalian S, Naidoo J, Levy B, Hellmann M, Brahmer JR, Chaft JE, Forde PM. Neoadjuvant nivolumab plus ipilimumab in resectable non-small cell lung cancer. J Immunother Cancer. 2020 Sep;8(2):e001282. doi: 10.1136/jitc-2020-001282. PMID:32929052

Rosner S, Reuss JE, Zahurak M, Zhang J, Zeng Z, Taube J, Anagnostou V, Smith KN, Riemer J, Illei PB, Broderick SR, Jones DR, Topalian SL, Pardoll DM, Brahmer JR, Chaft JE, Forde PM. Five-Year Clinical Outcomes after Neoadjuvant Nivolumab in Resectable Non-Small Cell Lung Cancer. Clin Cancer Res. 2023 Feb 16;29(4):705-710

Forde PM, Chaft JE, Smith KN, Anagnostou V, Cottrell TR, Hellmann MD, Zahurak M, Yang SC, Jones DR, Broderick S, Battafarano RJ, Velez MJ, Rekhtman N, Olah Z, Naidoo J, Marrone KA, Verde F, Guo H, Zhang J, Caushi JX, Chan HY, Sidhom JW, Scharpf RB, White J, Gabrielson E, Wang H, Rosner GL, Rusch V, Wolchok JD, Merghoub T, Taube JM, Velculescu VE, Topalian SL, Brahmer JR, Pardoll DM. Neoadjuvant PD-1 Blockade in Resectable Lung Cancer, N Engl J Med. 2018 May 24;378(21):1976-1986.

Activities & Honors


  • Fellowship Award, International Association for the Study of Lung Cancer (IASLC), 2013
  • Career Development Award, LUNGevity Lung Cancer Foundation , 2014 - 2017
  • Paul Carbone MD Fellowship Award, 2013
  • Director's Teaching Award in Clinical Science, SKCCC, 2014 - 2015
  • AACR-SU2C Phillip A. Sharp Innovation in Collaboration Award, 2016
  • ESMO Travel Award, 2016
  • Principal Investigator, Translational Team Science Award, US Department of Defense, 2020 - 2024
  • SITC Team Science Award, Society for Immunotherapy of Cancer, 2020
  • 2022 Daniel C. Ihde Lectureship Award for Medical Oncology, International Association for the Study of Lung Cancer
  • ECOG-ACRIN Young Investigator Award, 2023


  • American Society of Clinical Oncology
  • International Association for the Study of Lung Cancer
  • Society for Immunotherapy of Cancer
  • American Association for Cancer Research

Videos & Media

Recent News Articles and Media Coverage

Drug reduces size of some lung cancer tumors, relapse rate after surgery. Interview for article reporting on Forde et al. (April 16, 2018) NEJM paper

New studies show hope for turning immune system against lung cancer. Interview for article reporting on Forde et al. USA Today (April 16, 2018) NEJM paper

New Studies Show Immune Treatments Could Be Key in the Fight Against Lung Cancer. Interviewed for article reporting on Forde et al NEJM publication. TIME magazine (April 16, 2018), NEJM paper

Phase II Study Evaluates Chemotherapy and Immunotherapy in Patients With Malignant Pleural Mesothelioma, ASCO Post (July 10, 2020)

Combination Almost Doubles Survival in Untreated Mesothelioma, MedPage Today (November 11, 2021)

CheckMate 816: Neoadjuvant Nivolumab Plus Chemotherapy in Resectable NSCLC ASCO Postlink - (April 22, 2022)

Is this you? Edit Profile
back to top button